Enrique A. Conterno
Net Worth
Last updated:
What is Enrique A. Conterno net worth?
The estimated net worth of Mr. Enrique A. Conterno is at least $13,708,663 as of 7 Jul 2023. He owns shares worth $4,084,470 as insider, has earned $1,424,193 from insider trading and has received compensation worth at least $8,200,000 in FibroGen, Inc..
What is the salary of Enrique A. Conterno?
Mr. Enrique A. Conterno salary is $1,640,000 per year as Chief Executive Officer & Director in FibroGen, Inc..
How old is Enrique A. Conterno?
Mr. Enrique A. Conterno is 58 years old, born in 1967.
What stocks does Enrique A. Conterno currently own?
As insider, Mr. Enrique A. Conterno owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| FibroGen, Inc. (FGEN) | Chief Executive Officer & Director | 374,722 | $10.9 | $4,084,470 |
What does FibroGen, Inc. do?
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Enrique A. Conterno insider trading
FibroGen, Inc.
Mr. Enrique A. Conterno has made 9 insider trades between 2020-2023, according to the Form 4 filled with the SEC. Most recently he sold 1,880 units of FGEN stock worth $5,264 on 7 Jul 2023.
The largest trade he's ever made was exercising 24,672 units of FGEN stock on 8 Mar 2023. As of 7 Jul 2023 he still owns at least 374,722 units of FGEN stock.
FibroGen key executives
FibroGen, Inc. executives and other stock owners filed with the SEC:
- Dr. Elias Kouchakji (69) Senior Vice President of Clinical Devel., Drug Safety & Pharmacovigilance
- Dr. Mark Eisner M.D., M.P.H. (59) Chief Medical Officer
- Mr. Enrique A. Conterno (58) Chief Executive Officer & Director
- Mr. James A. Schoeneck (67) Chairman
- Mr. Pat Cotroneo (61) Executive Advisor to Chief Executive Officer
- Mr. Thane Wettig (60) Chief Commercial Officer